linjc16/ctgov huggingface dataset:
Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended?

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare outcomes of patients undergoing standard or extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer

Official Title
-----------------
A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer

Conditions
-----------------
Pancreatic Ductal Adenocarcinoma

Intervention / Treatment
-----------------
* Procedure: Pancreaticoduodenectomy with Standard lymphadenectomy
* Procedure: Pancreaticoduodenectomy with Extended lymphadenectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologic diagnosis of pancreatic ductal adenocarcinoma Signed the informed consents Exclusion Criteria: Pathologic diagnosis of other pancreatic cancers Pre-operative anti-cancer treatment Recurrence patients Patients with contraindication(hepatic/ respiratory/ renal dysfunction, etc ) Pre operative exam: Total bilirubin more than 250µmol/L AJCC stage IV Operation non radical

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Standard resection<br>Pancreaticoduodenectomy (child's digestive reconstruction); Standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b | Procedure: Pancreaticoduodenectomy with Standard lymphadenectomy<br>* Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b<br>|
| Experimental: Extended resection<br>Pancreaticoduodenectomy (child's digestive reconstruction)extended lymphadenectomy No8p 12a 12p 14c 14d 16 | Procedure: Pancreaticoduodenectomy with Extended lymphadenectomy<br>* Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality |  | 3yrs post-operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality |  | 1yr post-operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Standard lymphadenectomy, extended lymphadenectomy, pancreaticoduodenectomy
Attentional Bias in Body Dysmorphic Disorder

Study Overview
=================
Brief Summary
-----------------
Body Dysmorphic Disorder (BDD) participants will demonstrate greater attentional biases as compared to healthy control (HC) participants. Greater attention bias will be associated with greater distress. Greater attention bias will be associated with greater symptom severity.

Official Title
-----------------
Attentional Bias in Body Dysmorphic Disorder

Conditions
-----------------
Body Dysmorphic Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for BDD and healthy control participants: males and females 18 years of age or older sufficient fluency of English to understand study staff, procedures, and questionnaires ability to provide informed consent Inclusion for BDD participants only; primary diagnosis of Diagnostic and Statistical Manual 4th Edition (DSM-IV-TR) BDD BDD Yale-Brown Obsessive Compulsive Disorder score (Y-BOCS) of > 20 primary facial/head concern Exclusion Criteria: Major medical or neurological conditions schizophrenia, schizoaffective disorder, or any other current lifetime DSM-IV psychotic disorder that is not attributable to delusional BDD current suicidality current homicidality Exclusion criteria for healthy controls: Any current Axis I psychiatric illness history of BDD

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Body dysmorphic disorder (BDD) Participants<br>Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff. | |
| Healthy Controls<br>Males and females 18 years of age or older with ability to provide informed consent and understand study staff. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Attention Pattern | Gaze tracking via an Eyelink II eye tracker will determine perception of visual information. | Day 2 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective Units of Distress Scale (SUDS) | Participants will provide a distress score based on the facial images observed. | Day 2 | 
| Facial Attractiveness | Using a 9-point Likert scale, participants will rate the perceived most attractive and unattractive feature of their own and the control face. | Day 2 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
BDD
Diabetic Retinopathy Screening in General Practice

Study Overview
=================
Brief Summary
-----------------
Diabetic Retinopathy is a microvascular eye complication of diabetes, which can go unnoticed until permanent vision damage has occurred - in worst-case blindness. Timely retinopathy screenings reduce the risk of sight loss since the disease can be treated if detected in time. For people with type 2 diabetes, retinopathy screenings are typically performed by specialist at private ophthalmologists' practices, and individualized screening intervals based on retinopathy level and diabetes regulation are recommended. Unfortunately, 26% of people with type 2 diabetes do not follow their screening interval, and the attendance is too low compared to the national standard of minimum 90% of patients with diabetes who ought to follow the screening program. Consequently, actions must be taken to improve screening attendance in Denmark. The aim of this study is to investigate patients' acceptance of diabetic retinopathy screenings in general practice. Patients' acceptance is explored through a questionnaire developed for the study.

Official Title
-----------------
Diabetic Retinopathy Screenings in General Practice for People With Type 2 Diabetes

Conditions
-----------------
Type2 Diabetes, Diabetic Retinopathy

Intervention / Treatment
-----------------
* Diagnostic Test: Diabetic Retinopathy Screening


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with type 2 diabetes Understands Danish Age between 18-70 Exclusion Criteria: Blindness Cannot partake in second screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| People with type 2 diabetes<br>People diagnosed with type 2 diabetes age 18-70 | Diagnostic Test: Diabetic Retinopathy Screening<br>* Screenings are performed in the diabetes consultation in general practice<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients' acceptance of diabetic retinopathy screenings in general practice | Questionnaire | 1 day (the questionnarie is fufilled one time after the retinopaty screening in general practice) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Artificial Intelligence, Diabetic Retinopathy Screening, General practice, Primary care, Type 2 diabetes
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The safety of the treatment will also be studied.

Official Title
-----------------
Study of Dasatinib (BMS-354825) in Subjects With Chronic Myelogenous Leukemia With Accelerated or Myeloid or Lymphoid Blast Phase or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Who Are Resistant to or Intolerant of Imatinib Mesylate

Conditions
-----------------
Leukemia, Myeloid, Chronic, Leukemia, Lymphocytic, Acute, L2

Intervention / Treatment
-----------------
* Drug: Dasatinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of accelerated phase or blast phase CML or Ph+ ALL Intolerant or resistant to imatinib mesylate 18 years of age or older ECOG performance 0-2 (greater than 50% of time out of bed) Adequate liver and kidney function Exclusion Criteria: Pregnant or breastfeeding females History of significant cardiac disease History of significant bleeding disorder (not CML) Prisoners

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A1<br> | Drug: Dasatinib<br>* Tablets, Oral, 70 mg, Twice daily, 2 months.<br>* Other names: Sprycel;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Provide therapy to patients for which there is no therapeutic alternative |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety data collection |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Myeloid Leukemia Accelerated and Blast Phase, Leukemia, Acute, Philadelphia-Positive
Evaluation of the Sarcopenia in Hepatobiliary Surgery

Study Overview
=================
Brief Summary
-----------------
The sarcopenia is defined as a loss of muscle mass and a loss of muscle function ( strength or performance). Some studies showed that the sarcopenia increase the postoperative complications and the overall survival in abdominal surgery. But the sarcopenia is not evaluated in the Hepatobiliary surgery. This prospective, monconcentrique study aim to evaluate the prevalence of sarcopenia, and its associated morbimortality in hepatobiliary surgery for malignant or benign tumors.

Official Title
-----------------
Evaluation of the Prevalence, the Diagnosis Tests, and the Associated Morbimortality of Sarcopenia in Hepatobiliary Surgery

Conditions
-----------------
Sarcopenia, Hepatobiliary Disease, Postoperative Complications, Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hepatobiliary surgery scheduled surgery oral consent Exclusion Criteria: pregnancy patient under low protection emergency surgery hepatic encephalopathy stage II, III and IV

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of patients with a sarcopenia before having a hepatobiliary surgery mesured by impedancemetry and by the muscular force or the speed walking | for the man : i/impedancemetry BMI<8,87kg/m2 and ii/ a muscular force < 30kg or a walking speed <0,8m/s | 1 month | 
| the number of patients with a sarcopenia before having a hepatobiliary surgery mesured by impedancemetry and by the muscular force or the speed walking | for the woman: i/impedancemetry BMI<6,42kg/m2 and ii/muscular force < 20kg or a walking speed <0,8m/s | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparison between the impedancemetry and the abdominopevis CT for the diagnosis of sarcopenia | impedancemetry used to evaluate the muscular mass abdominopelvis CT evualate the muscular mass by measuring the muscular area on the L3 section | 3 months | 
| comparison of the postoperatives complications using the clavien dindo classsification between the patient with sarcopenia and the patient without sarcopenia. | postoperatives complications evualuated according the clavien dindo classification are : death, nausea, vomit, need of nasogastric tube, liver failure with jaundice, ascites, liver encephalopathy, biliary fistula, biliary peritonitis, hernia, parietal abcess, urinary infection, urinary retention, hematoma, pulmonary embolism, pulmonary infection, pleural effusion, atelectasis, renal failure, hyponatremia, hypernatremia, hypokaliema, hyperkaliema the post operative complication evaluate | 4 months |
Famotidine Outpatient COVID-19 Treatment Study

Study Overview
=================
Brief Summary
-----------------
A retrospective case series of patients who self-medicated with Famotidine during coronavirus disease 2019 (COVID-19). The study will collect de-identified patient reported outcome measures of patients with confirmed COVID-19 who self-medicated with Famotidine at any dose during the period of illness. Data will be collected by questionnaire and telephone interview. Inclusion criteria: Age>18; Ability to give written informed consent for study participation; Confirmed diagnosis of COVID-19; Use of Famotidine at any dose during period of COVID-19 illness

Detailed Description
-----------------
Famotidine is a histamine-2 receptor antagonist, widely available over-the-counter, and is safely used for suppression of gastric acid production over a wide range of doses from 20mg once daily to 160mg four times daily. In computer-based simulations, Famotidine has been identified as a potential inhibitor of the 3-chymotrypsin-like protease (3CLpro). In a propensity score matched retrospective cohort study a significantly reduced risk for death or intubation (adjusted hazard ratio 0.43, 95% confidence interval 0.21-0.88) was identified for patients with COVID-19 who were taking Famotidine before or at the point of hospital admission. Some individuals have self-medicated with Famotidine while being outpatients with COVID-19. This study is aimed at collecting patient reported outcome measures from such individuals.

Official Title
-----------------
Famotidine Use in Non-hospitalized Patients With COVID-19: A Case Series

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Drug: Famotidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years; Ability to give written informed consent; Confirmed COVID-19 diagnosis; Famotidine use during COVID-19 illness Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with COVID-19 taking Famotidine<br>Use of any dose of oral Famotidine during period of COVID-19 | Drug: Famotidine<br>* Use of oral Famotidine.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptomatic improvement | Symptoms assessed by severity scores on an ordinal scale; 1=not affected to 4= severely affected | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peripheral blood oxygen saturation | Oxygen saturation determined by pulse oximetry | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Famotidine
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the demographic characteristics, clinical features, diagnoses and treatments of AECOPD hospitalized patients in China, and disease prognosis and its economic burden.

Official Title
-----------------
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥18 years of age; hospitalized patients with main diagnosis as AECOPD. Exclusion Criteria: Patients diagnosed as active pulmonary tuberculosis, or acute left heart failure; Patients participating in clinical trials or intervention studies of drugs.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-hospital mortality | All-cause and cause-specific mortality will be described. | 12 months | 
| Readmission | Readmission rate caused by AECOPD within 1 month after discharged from hospital. | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause and cause-specific mortality | All-cause and cause-specific mortality will be described at different time points (1, 2, 3 years) | 3 years | 
| Recurrence of acute exacerbation of COPD | Frequency of AECOPD recurrence will be described during follow-ups, the date of first recurrence after discharge will be analysed. | 3 years | 
| Lung function and quality of life assessment | Lung function will be measured regularly, quality of life will be assessed by questionnaires | 3 years | 
| Healthcare costs | Direct costs of hospital stay will be recorded. | 12 months |
Complementary and Alternative Medical Trends: A Patient Survey in a University Based Clinic

Study Overview
=================
Brief Summary
-----------------
Patient survey identifying key elements of patient experience and decision-making processes regarding attendance University of California, Irvine (UCI)'s Integrative Medicine Clinic.

Detailed Description
-----------------
Patient survey to determine why patients come to UCI's integrative medicine clinic, whether they would prefer we accept insurance coverage, and what therapies they are using.

Official Title
-----------------
Complementary and Alternative Medical Therapy Trends: A Patient Survey in a University Based Clinic

Conditions
-----------------
Complementary and Alternative Therapies

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients 41 years of age or older English speaking Ability to provide informed consent Patient at Gottschalk Medical Plaza Integrative Medical Clinic Ability to complete survey Exclusion Criteria: Patient less than 41 years of age Inability to speak English Patient unable to provide informed consent Patient not being seen at Gottschalk medical Plaza Integrative Medical Clinic Incomplete survey

Ages Eligible for Study
-----------------
Minimum Age: 41 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Why People Chose Complementary and Alternative Therapies |  | Post-care | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
alternative medicine, complementary medicine, acupuncture, Chinese herbals
PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The overall goal of this project is to investigate the diagnostic performance of integrated F-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) and Dual Energy CT (DECT) imaging in determining the thoracic nodal status of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), and its impact on target volume delineation for image guided radiation therapy (IGRT) planning.

Official Title
-----------------
Application of Integrated PET and Dual Energy CT Imaging for Staging and Imaged Based Radiotherapy Treatment Planning in Lung Cancer

Conditions
-----------------
PET CT

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be eligible for the study: (All answers must be YES for subject to be eligible.) Subject must have a suspected SCLC or NSCLC. Subject must be 18-90 years of age. Subject must have been referred for a clinically indicated PET-CT. Subject must provide written informed consent prior to any study-related procedures being performed. Subject must be willing to comply with all clinical study procedures. Exclusion Criteria: The presence of the following excludes subjects from the study: (All answers must be NO for subject to be eligible.) Subject is a pregnant or nursing female. Exclude the possibility of pregnancy: By testing (serum or urine βHCG) within 24 hours before contrast agent administration, or By surgical sterilization, or Post-menopausal, with minimum one (1) year history without menses. Subject has impaired renal function (eGFR<30 mL/min). Subject has an acute psychiatric disorder or is cognitively impaired. Subject is using or is dependent on substances of abuse. Subject is unwilling to comply with the requirements of the protocol. Subject has an allergy against iodinated contrast agents and cannot be premedicated. Subject is in acute unstable condition.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PET-CT accuracy for lung tumor and thoracic adenopathy detection | Knowledge gained during this study may potentially allow for an improvement in PET-CT accuracy for lung tumor and thoracic adenopathy detection, and for a more accurate definition of the RT target, decreasing the radiation dose delivered to normal tissue. | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PET CT